Know Cancer

forgot password

PET-CT for Intraductal Papillary Mucinous Neoplasm (IPMN)

18 Years
90 Years
Open (Enrolling)
Intraductal Papillary Mucinous Neoplasm

Thank you

Trial Information

PET-CT for Intraductal Papillary Mucinous Neoplasm (IPMN)

Duct involved intraductal papillary mucinous neoplasm is associated with a 35-70%
(particularly involving the main duct) incidence of malignancy. Current guidelines recommend
pancreatic resection for fit patients with main or branch duct involved IPMN. Pancreatic
resection can be associated with morbidity and mortality. Reliable tests or biomarkers
accurately differentiating non-malignant from malignant duct involved IPMN are non-existent.
Test or biomarkers differentiating duct involved from duct uninvolved IPMN are also
inaccurate. Patients with suspected duct IPMN with symptoms have a higher chance of
associated malignancy. These findings are not specific for malignant IPMN so, if relied on,
they would results in missed malignancies as well as potentially unnecessary operations in a
significant percentage of patients. PET scanning has been studied retrospectively and
purported to be a highly reliable indicator og high grade dysplasia and/or invasive cancer
in patients with IPMN. Thus, PET could represent a future standard of care by some
authorities in the work-up of patients with IPMN. This proposal seeks to prove the
hypothesis that pancreas PET-CT can differentiate duct involved IPMN with malignancy from
duct involved IPMN without malignancy.

Inclusion Criteria:

- Patients will be eligible for the study if they have a clinical and/or cytopathologic
diagnosis of IPMN (primary or recurrent) with suspected main or branch duct

- A clinical diagnosis of IPMN with main duct involvement will be determined by the
surgeon caring for the patient. Main duct involvement may be suspected where there
is a significant radiographic character change (cystic dilation) in the main
pancreatic duct (independent of ductal diameter), a significant "step-up" in main
duct diameter (2-3 fold) or a significant segmental or diffuse dilation of the main
pancreatic duct (> or equal to 4mm) as defined by CT, MRCP, EUS or ERCP.

- All patients with a diagnosis (pathologic) or presumed diagnosis (based upon clinical
presentation) of IPMN and who are to undergo surgical treatment are eligible for the
study. This may include patients who have already undergone IPMN surgery in the past
and who are expected to undergo a second IPMN surgery.

- Patients with unrecoverable renal function on dialysis are eligible to undergo this

- Female patients of child-bearing age must have a negative urine or serum pregnancy
test prior to enrollment.

- Subjects must have medical insurance or Medicare willing to pay for the cost of this
PET-CT procedure or the CT portion of the procedure.

Exclusion Criteria:

- Patients who despite suspected duct involved IPMN are not fit surgical candidates and
thus will not undergo resection of their IPMN.

- Patients with uncontrolled serum glucose will not be eligible for the study due to
the unreliability of PET in these patients. Diabetic patients are eligible as long
as their glucose is reasonably controlled (as determined by the nuclear medicine
radiologists). The Department of Radiology has a Standard Operating Procedure in
place for the management of these patients which will be followed in this protocol.

- Pediatric patients are excluded from this study since IPMN is a diagnosis present in
adult patients.

- Female patients who are pregnant or who are currently breastfeeding.

- Patients with allergy to IV contrast have a relative contraindication to the study.
Some of these patients at the discretion of the investigator may undergo a standard
protocol of pre-IV contrast steroids to manage their allergic response. The
Department of Radiology has guidelines that will be followed in this protocol for
patients who have experienced an allergic reaction to IV contrast.

- Patients with renal insufficiency (creatinine > or equal to 2.0) have a relative
contraindication to the study. At the investigator's discretion these patients may
be enrolled and undergo PET-CT without IV contrast.

- Patients without insurance or Medicare coverage or patients with insurance/Medicare
coverage but insurer is unwilling to pay for the cost of the PET-CT procedure or the
CT portion of the procedure.

Type of Study:


Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

Pancreas PET-CT can differentiate duct involved IPMN with malignancy from duct involved IPMN without malignancy.

Outcome Time Frame:

Six months

Safety Issue:


Principal Investigator

Christian M Schmidt, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Indiana University


United States: Institutional Review Board

Study ID:




Start Date:

September 2009

Completion Date:

September 2021

Related Keywords:

  • Intraductal Papillary Mucinous Neoplasm
  • IPMN
  • Neoplasms



Indiana University Medical CenterIndianapolis, Indiana  46202